MDxHealth SA (MDXH) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN BE0974461940

Price
0.14 USD
Market cap
13.36 m USD
P/E (2025)
–
P/S (2025)
0.12
Dividend yield
0.00 %
Net margin
-31.07 %
Return on equity (ROE)
277.15 %
Return on assets (ROA)
-22.66 %

MDxHealth SA financials

Fiscal year20242025
Revenue90.05 m USD107.88 m USD
Gross profit55.14 m USD64.44 m USD
Operating income-24.72 m USD-15.40 m USD
EBIT-30.06 m USD-23.22 m USD
Net income-38.07 m USD-33.52 m USD
Diluted EPS – continuing operations-0.78 USD-0.67 USD

Full history since 2004, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.